Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Do We Have Enough Social Networks?
Jive is looking to get businesses use their software to increase collaboration, content movement and enterprise portals / intranets. Jive's mission is to change the way work gets done, but with nearly 1 billion Facebook users, 175M LinkedIn members and about 400 million tweets a day, are they late to the game?
Company Description
Jive Software, Inc. provides a social business software platform to businesses, government agencies, and other enterprises. Its Jive Engage Platform enables collaboration across two principal communities and employees within the enterprise, and customers and partners outside the enterprise. The company's Jive Engage Platform is used as a communications tool and collaborative workspace that supports and enhances knowledge sharing, facilitates communication within and across organizational boundaries, and enables individuals to work together to achieve common business goals.
JIVE Hasn't Beat Over The Last Year
Dating back to the December 2011 quarter, which was the last time that the company posted a positive earnings surprise. Of the five quarters since that time, there have been two meets and 3 negative earnings surprises.
Losses Increase as Revenues Grow
When you see a stock that has revenues increase and earnings per share decrease you start to scratch your head. Jive has posted revenue of $27M, $29M, $33M and $34M in each of the last four quarters respectively. Over the same period reported earnings per share fell from -$0.18, -$0.17, -$0.23, -$0.24. So the losses are getting bigger as revenues increase.
Projected Earnings Growth Drops
Topline growth has shown up, but the bottom line is projected to only see extended losses in 2013 and 2014. Just in the last six months, the Zacks Consensus Estimate for 2013 has moved from a loss of $0.47 to a loss of $1.06, a significant drop. At the same time, 2014 is not getting any better. In November 2012, the 2014 estimate moved from -$0.29 to the current level of a loss of $1.00.
Valuation
The valuation picture for JIVE is a challenging one due to the negative earnings. The stand by valuation metrics like Price to Earnings are all not meaningful due to the negative earnings. Price to book of 8.3x is almost double that of the industry average. The price to sales metric also shows a significant premium as well. Still the company is projected to see revenue growth of 33% this year and 29% next year. Earnings growth of -47% for 2013 is a major detractor, but 5.7% growth in earnings for 2014 shows that there is light at the end of the tunnel. The problem is the tunnel is awfully long.
The Chart
A quick look at the price and consensus shows that the young company debuted with some high expectations. Since that time analysts have continued to move their earnings estimates lower and lower. With the stock comfortably in the teens, shareholders are more than likely going to stick with it until single digits appear imminent.
Brian Bolan is a Stock Strategist for Zacks.com. He is the Editor in charge of the Zacks Home Run Investor service, a Buy and Hold service where he recommends the stocks in the portfolio.
Brian is also the editor of Breakout GrowthTrader a trading service that focuses on small cap stocks and also carries a risk limiting strategy. Subscribers get daily emails along with buy, and sell alerts.
Follow Brian Bolan on twitter at @BBolan1
Like Brian Bolan on Facebook
Read the full Snapshot Report on JIVE